Comparison · NCT03439345-6c82ceb4
Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With The Development of Macular Oedema
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With The Development of Macular Oedema. Trial comparisons, record NCT03439345-6c82ceb4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03439345-6c82ceb4
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0382 | 0.0254 | 0.0572 | wilson | |
| Risk in group 2 | 0.0748 | 0.056 | 0.0992 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0366 | -0.0642 | -0.0099 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.511 | 0.31 | 0.843 | log | |
| Odds ratio, group 1 over group 2 | 0.491 | 0.29 | 0.832 | log | |
| Number needed to treat, for one fewer participant with the outcome on Fenofibrate 145 mg than on Placebo Oral Tablet | 27.3 | 15.6 | 101 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Fenofibrate 145 mg | Fenofibrate 145 mg: One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease) | 22 | 576 | OG000 |
| Group 2 | Placebo Oral Tablet | Placebo Oral Tablet: One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease) | 43 | 575 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With The Development of Macular Oedema
- Description
- The accumulation of macular fluid as determined by optical coherence tomography (OCT) imaging or on adverse event report
- Time frame
- 4.0 years (interquartile range, 3.6 to 4.3) years
- Population
- Intention-to-treat comparisons among all randomised participants of the effects of allocation to fenofibrate versus placebo during the scheduled treatment period on time to the first occurrence
Source ClinicalTrials.gov
Trial
- Title
- Lowering Events in Non-proliferative Retinopathy in Scotland
- NCT number
- NCT03439345
- Phases
- PHASE4
- Conditions
- Diabetic Retinopathy
- Interventions
- Fenofibrate 145 mg, Placebo Oral Tablet
- Lead sponsor
- University of Oxford
- Results first posted
- 2025-05-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03439345?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03439345-6c82ceb4